Gozetotide

Summary

Gozetotide (CHEMBL3578202) is an approved small molecule; indicated across 1 condition including metastatic prostate carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 5
• Chemistry: 947 Da · C44H62N6O17

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3578202
Name	Gozetotide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	60143283
Molecular formula	C44H62N6O17
Molecular weight	947
InChIKey	QJUIUFGOTBRHKP-LQJZCPKCSA-N

SMILES: C1=CC(=C(C=C1CCC(=O)NCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)CN(CCN(CC2=C(C=CC(=C2)CCC(=O)O)O)CC(=O)O)CC(=O)O)O

IUPAC name: (2S)-2-[[(1S)-1-carboxy-5-[6-[3-[3-[[2-[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]methyl]-4-hydroxyphenyl]propanoylamino]hexanoylamino]pentyl]carbamoylamino]pentanedioic acid

Also known as: Gozetotide, Psma-11, Psma-hbed-cc, GOZETOTIDE

Parent form; salt/anhydrous children: CHEMBL4650355, CHEMBL5095039

Patent coverage: 213 distinct patent families (466 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 420 (90%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Glutamate carboxypeptidase 2.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FOLH1	10.74	Ki	0.02	nM	CHEMBL_ACT_15602242
FOLH1	7.92	Ki	12	nM	CHEMBL_ACT_25071879

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
metastatic prostate carcinoma	2	MONDO:0004956	EFO:0000196

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
Not specified	3
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02659527	PHASE3	COMPLETED	PET/MRI in Patients With Suspected Prostate Cancer
NCT03181867	PHASE2	ACTIVE_NOT_RECRUITING	18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
NCT07455097	Not specified	ACTIVE_NOT_RECRUITING	COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)
NCT04452136	Not specified	APPROVED_FOR_MARKETING	Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer
NCT04825652	Not specified	NO_LONGER_AVAILABLE	177Lu-PSMA-617 Managed Access Program for mCRPC Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).